Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Short Interest Up 84.0% in June

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) was the recipient of a significant growth in short interest in the month of June. As of June 30th, there was short interest totaling 709,762 shares, a growth of 84.0% from the June 15th total of 385,765 shares. Based on an average daily trading volume, of 507,169 shares, the days-to-cover ratio is currently 1.4 days. Currently, 5.2% of the company’s shares are short sold.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Renaissance Technologies LLC raised its position in Lixte Biotechnology by 47.0% in the 4th quarter. Renaissance Technologies LLC now owns 107,500 shares of the company’s stock valued at $422,000 after buying an additional 34,350 shares during the last quarter. Federation des caisses Desjardins du Quebec raised its stake in shares of Lixte Biotechnology by 83.6% in the fourth quarter. Federation des caisses Desjardins du Quebec now owns 93,380 shares of the company’s stock valued at $367,000 after buying an additional 42,530 shares during the period. DRW Securities LLC lifted its holdings in Lixte Biotechnology by 11.6% during the fourth quarter. DRW Securities LLC now owns 54,126 shares of the company’s stock valued at $213,000 after purchasing an additional 5,645 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Lixte Biotechnology by 25.9% during the 4th quarter. Geode Capital Management LLC now owns 52,163 shares of the company’s stock valued at $205,000 after buying an additional 10,722 shares in the last quarter. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Lixte Biotechnology during the second quarter worth $330,000. Institutional investors and hedge funds own 5.10% of the company’s stock.

Lixte Biotechnology Price Performance

Shares of Lixte Biotechnology stock opened at $7.51 on Friday. The firm has a market capitalization of $112.80 million, a P/E ratio of -6.65 and a beta of 1.24. Lixte Biotechnology has a fifty-two week low of $2.02 and a fifty-two week high of $8.38. The company’s 50 day moving average price is $6.71 and its two-hundred day moving average price is $4.48.

Lixte Biotechnology (NASDAQ:LIXT) last posted its earnings results on Thursday, May 14th. The company reported ($0.18) earnings per share for the quarter.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Weiss Ratings downgraded Lixte Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, May 26th. Wall Street Zen raised Lixte Biotechnology to a “hold” rating in a report on Saturday, June 13th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Lixte Biotechnology has an average rating of “Sell”.

About Lixte Biotechnology

Lixte Biotechnology Holdings, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for the treatment of cancer. The company’s research centers on selectively targeting key enzymes and pathways involved in DNA damage response and cell cycle regulation, with the goal of creating novel oncology drugs that improve patient outcomes with manageable safety profiles.

Lixte’s lead programs include selective inhibitors of cell cycle checkpoints and related targets, designed to potentiate the effects of standard-of-care chemotherapies and overcome resistance mechanisms.